Notices. Notice; correction
213 words·~1 min read·
/register/2019/08/30/2019-18730·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4154-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-D-2991] Pediatric Rare Diseases—A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry; Availability; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. SUMMARY: The Food and Drug Administration is correcting a notice entitled “Pediatric Rare Diseases—A Collaborative Approach for Drug Development Using Gaucher Disease as a Model;
Draft Guidance for Industry; Availability” that appeared in the **Federal Register** of December 7, 2017. The document announced the availability of a draft guidance focusing on drug development for pediatric patients with Gaucher disease. The document was published with the incorrect docket number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.
SUPPLEMENTARY INFORMATION: In the **Federal Register** of Thursday, December 7, 2017 (82 FR 57759), in FR Doc. 2017-26357, the following correction is made: On page 57759, in the first column, in the document heading and in the third column under *Instructions,* the docket number “FDA-2017-N-6476” is corrected to read “FDA-2017-D-2991”. Dated: August 26, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019-18730 Filed 8-29-19; 8:45 am]